BioJENC, LLC

Tumor vaccines

BioJENC
Tumor vaccines
Microbial detection
Contact Us
Tumor vaccines:

BioJENC has researched extensively to find links between virus and human cancer including brain tumors and has identified a viral protein with sequence motifs similar to a tumor-associated protein.  Given that these two proteins also share a similar functionality, it is likely that these sequence motifs may play an essential role contributing to their common functionality.  BioJENC has designed peptides for vaccine development targeting these sequence motifs. 
 
Areas of special interest: Astrocytomas and specifically Rosetted Glioneuroma

Rosetted Glioneuroma (RG) is a relatively new name for a type of primary brain tumor, hence not too many cases have been reported.  RG features distinct neurocytic rosettes and a glioma (similar to pilocytic astrocytoma).  Some patients previously diagnosed with Juvenile Pilocytic Astrocytoma might show characteristics of Rosetted Glioneuroma in tumor tissues.  Overexpression and/or mutation of p53 and epidermal growth factor receptor have been related to low-grade and high-grade astrocytomas. 

 

BioJENC is interested in developing antibodies and/or inhibitors with specificities against these altered proteins.  Other proteins related to tumor growth and apoptosis are also included in our R&D.  Progress of our R&D will be posted as it becomes available, or contact us for specific information.  If you have information that may help expedite our study, please contact us.  Together, our wish to slow or stop the growth of tumors may come true. 

 

References:

Preusser M. et al.: Rosette-forming glioneuronal tumor of the fourth ventricle.  Acta Neuropathol (Berl). 2003 Nov; 106(5):506-8. Epub 2003 Aug 12.

 

Komori T. et al.: A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol. 2002 May; 26(5):582-91.

 

Pollack IF, Finkelstein SD, Woods J, et al.: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 (6): 420-7, 2002.

 

For more information on astrocytomas, visit www.cancer.gov

To share your information regarding Rosetted Glioneuroma or ask for further information, please contact us.

BioJENC, LLC., Louisiana Emerging Technology Center, Baton Rouge, LA 70803. USA. Tel: 225-615-8934, FAX: 225-615-8910. 

©2005-2012 BioJENC, LLC.  Terms and Conditions of Use